http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 05 Jun 2026 18:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Knight+Announces+Early+Warning+Filing+Regarding+Shares+of%C2%A0Crescita/26612440.html <p align="justify">MONTREAL, June 05, 2026 (GLOBE NEWSWIRE) -- This press release is disseminated by Knight Therapeutics Inc. (&quot;Knight&quot;) (TSX:GUD), a pan-American (ex-US) pharmaceutical company, as required by Regulation 62-103 respecting the Early Warning System and Related Take-Over Bid and Insider Reporting Issues regarding securities of Crescita Therapeutics Inc. (&quot;Crescita&quot;). </p> <p align="justify">Crescita has announced the closing of the previously announced plan of arrangement (the “Arrangement”) with ClinActiv Holdings Inc. (“ClinActiv”) and its wholly-owned subsidiary (the “Purchaser”), pursuant to which the Purchaser acquired all the issued and outstanding common shares of Crescita (the “Shares”) in exchange for a cash consideration of $0.80 per Share. </p> http://www.streetinsider.com/Press+Releases/Knight+Announces+Early+Warning+Filing+Regarding+Shares+of%C2%A0Crescita/26612440.html Fri, 05 Jun 2026 18:00:00 -0400 A.02472330 GUD O.08133168 O.17511696 http://www.streetinsider.com/Press+Releases/Knight+Announces+Early+Warning+Filing+Regarding+Shares+of%C2%A0Crescita/26612440.html <p align="justify">MONTREAL, June 05, 2026 (GLOBE NEWSWIRE) -- This press release is disseminated by Knight Therapeutics Inc. (&quot;Knight&quot;) (TSX:GUD), a pan-American (ex-US) pharmaceutical company, as required by Regulation 62-103 respecting the Early Warning System and Related Take-Over Bid and Insider Reporting Issues regarding securities of Crescita Therapeutics Inc. (&quot;Crescita&quot;). </p> <p align="justify">Crescita has announced the closing of the previously announced plan of arrangement (the “Arrangement”) with ClinActiv Holdings Inc. (“ClinActiv”) and its wholly-owned subsidiary (the “Purchaser”), pursuant to which the Purchaser acquired all the issued and outstanding common shares of Crescita (the “Shares”) in exchange for a cash consideration of $0.80 per Share. </p> http://www.streetinsider.com/Press+Releases/Knight+Announces+Early+Warning+Filing+Regarding+Shares+of%C2%A0Crescita/26612440.html Fri, 05 Jun 2026 18:00:00 -0400 A.02472330 GUD O.08133168 O.17511696 http://www.streetinsider.com/Press+Releases/Knight+Announces+Early+Warning+Filing+Regarding+Shares+of%C2%A0Crescita/26612440.html <p align="justify">MONTREAL, June 05, 2026 (GLOBE NEWSWIRE) -- This press release is disseminated by Knight Therapeutics Inc. (&quot;Knight&quot;) (TSX:GUD), a pan-American (ex-US) pharmaceutical company, as required by Regulation 62-103 respecting the Early Warning System and Related Take-Over Bid and Insider Reporting Issues regarding securities of Crescita Therapeutics Inc. (&quot;Crescita&quot;). </p> <p align="justify">Crescita has announced the closing of the previously announced plan of arrangement (the “Arrangement”) with ClinActiv Holdings Inc. (“ClinActiv”) and its wholly-owned subsidiary (the “Purchaser”), pursuant to which the Purchaser acquired all the issued and outstanding common shares of Crescita (the “Shares”) in exchange for a cash consideration of $0.80 per Share. </p> http://www.streetinsider.com/Press+Releases/Knight+Announces+Early+Warning+Filing+Regarding+Shares+of%C2%A0Crescita/26612440.html Fri, 05 Jun 2026 18:00:00 -0400 A.02472330 GUD O.08133168 O.17511696 http://www.streetinsider.com/Press+Releases/Knight+Announces+Early+Warning+Filing+Regarding+Shares+of%C2%A0Crescita/26612440.html <p align="justify">MONTREAL, June 05, 2026 (GLOBE NEWSWIRE) -- This press release is disseminated by Knight Therapeutics Inc. (&quot;Knight&quot;) (TSX:GUD), a pan-American (ex-US) pharmaceutical company, as required by Regulation 62-103 respecting the Early Warning System and Related Take-Over Bid and Insider Reporting Issues regarding securities of Crescita Therapeutics Inc. (&quot;Crescita&quot;). </p> <p align="justify">Crescita has announced the closing of the previously announced plan of arrangement (the “Arrangement”) with ClinActiv Holdings Inc. (“ClinActiv”) and its wholly-owned subsidiary (the “Purchaser”), pursuant to which the Purchaser acquired all the issued and outstanding common shares of Crescita (the “Shares”) in exchange for a cash consideration of $0.80 per Share. </p> http://www.streetinsider.com/Press+Releases/Knight+Announces+Early+Warning+Filing+Regarding+Shares+of%C2%A0Crescita/26612440.html Fri, 05 Jun 2026 18:00:00 -0400 A.02472330 GUD O.08133168 O.17511696 http://www.streetinsider.com/Globe+Newswire/Knight+Announces+Early+Warning+Filing+Regarding+Shares+of%C2%A0Crescita/26612440.html <p align="justify">MONTREAL, June 05, 2026 (GLOBE NEWSWIRE) -- This press release is disseminated by Knight Therapeutics Inc. (&quot;Knight&quot;) (TSX:GUD), a pan-American (ex-US) pharmaceutical company, as required by Regulation 62-103 respecting the Early Warning System and Related Take-Over Bid and Insider Reporting Issues regarding securities of Crescita Therapeutics Inc. (&quot;Crescita&quot;). </p> <p align="justify">Crescita has announced the closing of the previously announced plan of arrangement (the “Arrangement”) with ClinActiv Holdings Inc. (“ClinActiv”) and its wholly-owned subsidiary (the “Purchaser”), pursuant to which the Purchaser acquired all the issued and outstanding common shares of Crescita (the “Shares”) in exchange for a cash consideration of $0.80 per Share. </p> http://www.streetinsider.com/Globe+Newswire/Knight+Announces+Early+Warning+Filing+Regarding+Shares+of%C2%A0Crescita/26612440.html Fri, 05 Jun 2026 18:00:00 -0400 A.02472330 GUD O.08133168 O.17511696 http://www.streetinsider.com/Globe+Newswire/Knight+Announces+Early+Warning+Filing+Regarding+Shares+of%C2%A0Crescita/26612440.html <p align="justify">MONTREAL, June 05, 2026 (GLOBE NEWSWIRE) -- This press release is disseminated by Knight Therapeutics Inc. (&quot;Knight&quot;) (TSX:GUD), a pan-American (ex-US) pharmaceutical company, as required by Regulation 62-103 respecting the Early Warning System and Related Take-Over Bid and Insider Reporting Issues regarding securities of Crescita Therapeutics Inc. (&quot;Crescita&quot;). </p> <p align="justify">Crescita has announced the closing of the previously announced plan of arrangement (the “Arrangement”) with ClinActiv Holdings Inc. (“ClinActiv”) and its wholly-owned subsidiary (the “Purchaser”), pursuant to which the Purchaser acquired all the issued and outstanding common shares of Crescita (the “Shares”) in exchange for a cash consideration of $0.80 per Share. </p> http://www.streetinsider.com/Globe+Newswire/Knight+Announces+Early+Warning+Filing+Regarding+Shares+of%C2%A0Crescita/26612440.html Fri, 05 Jun 2026 18:00:00 -0400 A.02472330 GUD O.08133168 O.17511696 http://www.streetinsider.com/Globe+Newswire/Knight+Announces+Early+Warning+Filing+Regarding+Shares+of%C2%A0Crescita/26612440.html <p align="justify">MONTREAL, June 05, 2026 (GLOBE NEWSWIRE) -- This press release is disseminated by Knight Therapeutics Inc. (&quot;Knight&quot;) (TSX:GUD), a pan-American (ex-US) pharmaceutical company, as required by Regulation 62-103 respecting the Early Warning System and Related Take-Over Bid and Insider Reporting Issues regarding securities of Crescita Therapeutics Inc. (&quot;Crescita&quot;). </p> <p align="justify">Crescita has announced the closing of the previously announced plan of arrangement (the “Arrangement”) with ClinActiv Holdings Inc. (“ClinActiv”) and its wholly-owned subsidiary (the “Purchaser”), pursuant to which the Purchaser acquired all the issued and outstanding common shares of Crescita (the “Shares”) in exchange for a cash consideration of $0.80 per Share. </p> http://www.streetinsider.com/Globe+Newswire/Knight+Announces+Early+Warning+Filing+Regarding+Shares+of%C2%A0Crescita/26612440.html Fri, 05 Jun 2026 18:00:00 -0400 A.02472330 GUD O.08133168 O.17511696 http://www.streetinsider.com/Globe+Newswire/Knight+Announces+Early+Warning+Filing+Regarding+Shares+of%C2%A0Crescita/26612440.html <p align="justify">MONTREAL, June 05, 2026 (GLOBE NEWSWIRE) -- This press release is disseminated by Knight Therapeutics Inc. (&quot;Knight&quot;) (TSX:GUD), a pan-American (ex-US) pharmaceutical company, as required by Regulation 62-103 respecting the Early Warning System and Related Take-Over Bid and Insider Reporting Issues regarding securities of Crescita Therapeutics Inc. (&quot;Crescita&quot;). </p> <p align="justify">Crescita has announced the closing of the previously announced plan of arrangement (the “Arrangement”) with ClinActiv Holdings Inc. (“ClinActiv”) and its wholly-owned subsidiary (the “Purchaser”), pursuant to which the Purchaser acquired all the issued and outstanding common shares of Crescita (the “Shares”) in exchange for a cash consideration of $0.80 per Share. </p> http://www.streetinsider.com/Globe+Newswire/Knight+Announces+Early+Warning+Filing+Regarding+Shares+of%C2%A0Crescita/26612440.html Fri, 05 Jun 2026 18:00:00 -0400 A.02472330 GUD O.08133168 O.17511696 http://www.streetinsider.com/Press+Releases/Knight+to+Present+at+the+Jefferies+2026+Healthcare+Conference+in+New+York+City/26561111.html <p align="justify">MONTREAL, May 28, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (&quot;Knight&quot;) a leading pan-America (ex-US) pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present at the <strong>Jefferies 2026 Healthcare Conference</strong> on Thursday, June 4, 2026 at 2:35 PM ET in New York City. A copy of the presentation will be available at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=5x3Z8k-EH-oaKTYTgCIyxfora49tSE4W-vbdB86ofNpuz6v5YbHmep37zmVTWNDjlJm7vO1dB-r60rycWFDPUw==" rel="nofollow" target="_blank">www.knighttx.com</a>.</p> <p><strong>About Knight Therapeutics Inc.</strong></p> <p align="justify">Knight Therapeutics Inc., headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. http://www.streetinsider.com/Press+Releases/Knight+to+Present+at+the+Jefferies+2026+Healthcare+Conference+in+New+York+City/26561111.html Thu, 28 May 2026 07:30:00 -0400 A.50201081 GUD O.01519837 O.17511696 http://www.streetinsider.com/Press+Releases/Knight+to+Present+at+the+Jefferies+2026+Healthcare+Conference+in+New+York+City/26561111.html <p align="justify">MONTREAL, May 28, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (&quot;Knight&quot;) a leading pan-America (ex-US) pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present at the <strong>Jefferies 2026 Healthcare Conference</strong> on Thursday, June 4, 2026 at 2:35 PM ET in New York City. A copy of the presentation will be available at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=5x3Z8k-EH-oaKTYTgCIyxfora49tSE4W-vbdB86ofNpuz6v5YbHmep37zmVTWNDjlJm7vO1dB-r60rycWFDPUw==" rel="nofollow" target="_blank">www.knighttx.com</a>.</p> <p><strong>About Knight Therapeutics Inc.</strong></p> <p align="justify">Knight Therapeutics Inc., headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. http://www.streetinsider.com/Press+Releases/Knight+to+Present+at+the+Jefferies+2026+Healthcare+Conference+in+New+York+City/26561111.html Thu, 28 May 2026 07:30:00 -0400 A.50201081 GUD O.01519837 O.17511696 http://www.streetinsider.com/Press+Releases/Knight+to+Present+at+the+Jefferies+2026+Healthcare+Conference+in+New+York+City/26561111.html <p align="justify">MONTREAL, May 28, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (&quot;Knight&quot;) a leading pan-America (ex-US) pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present at the <strong>Jefferies 2026 Healthcare Conference</strong> on Thursday, June 4, 2026 at 2:35 PM ET in New York City. A copy of the presentation will be available at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=5x3Z8k-EH-oaKTYTgCIyxfora49tSE4W-vbdB86ofNpuz6v5YbHmep37zmVTWNDjlJm7vO1dB-r60rycWFDPUw==" rel="nofollow" target="_blank">www.knighttx.com</a>.</p> <p><strong>About Knight Therapeutics Inc.</strong></p> <p align="justify">Knight Therapeutics Inc., headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. http://www.streetinsider.com/Press+Releases/Knight+to+Present+at+the+Jefferies+2026+Healthcare+Conference+in+New+York+City/26561111.html Thu, 28 May 2026 07:30:00 -0400 A.50201081 GUD O.01519837 O.17511696 http://www.streetinsider.com/Press+Releases/Knight+to+Present+at+the+Jefferies+2026+Healthcare+Conference+in+New+York+City/26561111.html <p align="justify">MONTREAL, May 28, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (&quot;Knight&quot;) a leading pan-America (ex-US) pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present at the <strong>Jefferies 2026 Healthcare Conference</strong> on Thursday, June 4, 2026 at 2:35 PM ET in New York City. A copy of the presentation will be available at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=5x3Z8k-EH-oaKTYTgCIyxfora49tSE4W-vbdB86ofNpuz6v5YbHmep37zmVTWNDjlJm7vO1dB-r60rycWFDPUw==" rel="nofollow" target="_blank">www.knighttx.com</a>.</p> <p><strong>About Knight Therapeutics Inc.</strong></p> <p align="justify">Knight Therapeutics Inc., headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. http://www.streetinsider.com/Press+Releases/Knight+to+Present+at+the+Jefferies+2026+Healthcare+Conference+in+New+York+City/26561111.html Thu, 28 May 2026 07:30:00 -0400 A.50201081 GUD O.01519837 O.17511696 http://www.streetinsider.com/Globe+Newswire/Knight+to+Present+at+the+Jefferies+2026+Healthcare+Conference+in+New+York+City/26561111.html <p align="justify">MONTREAL, May 28, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (&quot;Knight&quot;) a leading pan-America (ex-US) pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present at the <strong>Jefferies 2026 Healthcare Conference</strong> on Thursday, June 4, 2026 at 2:35 PM ET in New York City. A copy of the presentation will be available at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=5x3Z8k-EH-oaKTYTgCIyxfora49tSE4W-vbdB86ofNpuz6v5YbHmep37zmVTWNDjlJm7vO1dB-r60rycWFDPUw==" rel="nofollow" target="_blank">www.knighttx.com</a>.</p> <p><strong>About Knight Therapeutics Inc.</strong></p> <p align="justify">Knight Therapeutics Inc., headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. http://www.streetinsider.com/Globe+Newswire/Knight+to+Present+at+the+Jefferies+2026+Healthcare+Conference+in+New+York+City/26561111.html Thu, 28 May 2026 07:30:00 -0400 A.50201081 GUD O.01519837 O.17511696 http://www.streetinsider.com/Globe+Newswire/Knight+to+Present+at+the+Jefferies+2026+Healthcare+Conference+in+New+York+City/26561111.html <p align="justify">MONTREAL, May 28, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (&quot;Knight&quot;) a leading pan-America (ex-US) pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present at the <strong>Jefferies 2026 Healthcare Conference</strong> on Thursday, June 4, 2026 at 2:35 PM ET in New York City. A copy of the presentation will be available at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=5x3Z8k-EH-oaKTYTgCIyxfora49tSE4W-vbdB86ofNpuz6v5YbHmep37zmVTWNDjlJm7vO1dB-r60rycWFDPUw==" rel="nofollow" target="_blank">www.knighttx.com</a>.</p> <p><strong>About Knight Therapeutics Inc.</strong></p> <p align="justify">Knight Therapeutics Inc., headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. http://www.streetinsider.com/Globe+Newswire/Knight+to+Present+at+the+Jefferies+2026+Healthcare+Conference+in+New+York+City/26561111.html Thu, 28 May 2026 07:30:00 -0400 A.50201081 GUD O.01519837 O.17511696 http://www.streetinsider.com/Globe+Newswire/Knight+to+Present+at+the+Jefferies+2026+Healthcare+Conference+in+New+York+City/26561111.html <p align="justify">MONTREAL, May 28, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (&quot;Knight&quot;) a leading pan-America (ex-US) pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present at the <strong>Jefferies 2026 Healthcare Conference</strong> on Thursday, June 4, 2026 at 2:35 PM ET in New York City. A copy of the presentation will be available at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=5x3Z8k-EH-oaKTYTgCIyxfora49tSE4W-vbdB86ofNpuz6v5YbHmep37zmVTWNDjlJm7vO1dB-r60rycWFDPUw==" rel="nofollow" target="_blank">www.knighttx.com</a>.</p> <p><strong>About Knight Therapeutics Inc.</strong></p> <p align="justify">Knight Therapeutics Inc., headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. http://www.streetinsider.com/Globe+Newswire/Knight+to+Present+at+the+Jefferies+2026+Healthcare+Conference+in+New+York+City/26561111.html Thu, 28 May 2026 07:30:00 -0400 A.50201081 GUD O.01519837 O.17511696 http://www.streetinsider.com/Globe+Newswire/Knight+to+Present+at+the+Jefferies+2026+Healthcare+Conference+in+New+York+City/26561111.html <p align="justify">MONTREAL, May 28, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (&quot;Knight&quot;) a leading pan-America (ex-US) pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present at the <strong>Jefferies 2026 Healthcare Conference</strong> on Thursday, June 4, 2026 at 2:35 PM ET in New York City. A copy of the presentation will be available at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=5x3Z8k-EH-oaKTYTgCIyxfora49tSE4W-vbdB86ofNpuz6v5YbHmep37zmVTWNDjlJm7vO1dB-r60rycWFDPUw==" rel="nofollow" target="_blank">www.knighttx.com</a>.</p> <p><strong>About Knight Therapeutics Inc.</strong></p> <p align="justify">Knight Therapeutics Inc., headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. http://www.streetinsider.com/Globe+Newswire/Knight+to+Present+at+the+Jefferies+2026+Healthcare+Conference+in+New+York+City/26561111.html Thu, 28 May 2026 07:30:00 -0400 A.50201081 GUD O.01519837 O.17511696 http://www.streetinsider.com/Press+Releases/Knight+Therapeutics+Announces+Launch+of+TAVALISSE%C2%AE+in+Mexico/26559343.html <p align="justify">MONTREAL, May 27, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) (&quot;Knight&quot;) a pan-American (ex-US) pharmaceutical company, announced today the launch of TAVALISSE® (fostamatinib disodium hexahydrate) in Mexico, for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.1</p> <p align="justify">“Managing chronic ITP remains challenging, as patients often respond sub-optimally to available therapies and many continue to face a persistent risk of bleeding despite multiple treatment attempts. The introduction of fostamatinib in Mexico provides physicians with an important new therapeutic option, supported by solid clinical http://www.streetinsider.com/Press+Releases/Knight+Therapeutics+Announces+Launch+of+TAVALISSE%C2%AE+in+Mexico/26559343.html Wed, 27 May 2026 18:00:00 -0400 A.38925042 A.50201081 GUD O.01519837 O.03285412 O.17511696 http://www.streetinsider.com/Press+Releases/Knight+Therapeutics+Announces+Launch+of+TAVALISSE%C2%AE+in+Mexico/26559343.html <p align="justify">MONTREAL, May 27, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) (&quot;Knight&quot;) a pan-American (ex-US) pharmaceutical company, announced today the launch of TAVALISSE® (fostamatinib disodium hexahydrate) in Mexico, for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.1</p> <p align="justify">“Managing chronic ITP remains challenging, as patients often respond sub-optimally to available therapies and many continue to face a persistent risk of bleeding despite multiple treatment attempts. The introduction of fostamatinib in Mexico provides physicians with an important new therapeutic option, supported by solid clinical http://www.streetinsider.com/Press+Releases/Knight+Therapeutics+Announces+Launch+of+TAVALISSE%C2%AE+in+Mexico/26559343.html Wed, 27 May 2026 18:00:00 -0400 A.38925042 A.50201081 GUD O.01519837 O.03285412 O.17511696 http://www.streetinsider.com/Press+Releases/Knight+Therapeutics+Announces+Launch+of+TAVALISSE%C2%AE+in+Mexico/26559343.html <p align="justify">MONTREAL, May 27, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) (&quot;Knight&quot;) a pan-American (ex-US) pharmaceutical company, announced today the launch of TAVALISSE® (fostamatinib disodium hexahydrate) in Mexico, for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.1</p> <p align="justify">“Managing chronic ITP remains challenging, as patients often respond sub-optimally to available therapies and many continue to face a persistent risk of bleeding despite multiple treatment attempts. The introduction of fostamatinib in Mexico provides physicians with an important new therapeutic option, supported by solid clinical http://www.streetinsider.com/Press+Releases/Knight+Therapeutics+Announces+Launch+of+TAVALISSE%C2%AE+in+Mexico/26559343.html Wed, 27 May 2026 18:00:00 -0400 A.38925042 A.50201081 GUD O.01519837 O.03285412 O.17511696 http://www.streetinsider.com/Press+Releases/Knight+Therapeutics+Announces+Launch+of+TAVALISSE%C2%AE+in+Mexico/26559343.html <p align="justify">MONTREAL, May 27, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) (&quot;Knight&quot;) a pan-American (ex-US) pharmaceutical company, announced today the launch of TAVALISSE® (fostamatinib disodium hexahydrate) in Mexico, for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.1</p> <p align="justify">“Managing chronic ITP remains challenging, as patients often respond sub-optimally to available therapies and many continue to face a persistent risk of bleeding despite multiple treatment attempts. The introduction of fostamatinib in Mexico provides physicians with an important new therapeutic option, supported by solid clinical http://www.streetinsider.com/Press+Releases/Knight+Therapeutics+Announces+Launch+of+TAVALISSE%C2%AE+in+Mexico/26559343.html Wed, 27 May 2026 18:00:00 -0400 A.38925042 A.50201081 GUD O.01519837 O.03285412 O.17511696 http://www.streetinsider.com/Press+Releases/Knight+Therapeutics+Announces+Launch+of+TAVALISSE%C2%AE+in+Mexico/26559343.html <p align="justify">MONTREAL, May 27, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) (&quot;Knight&quot;) a pan-American (ex-US) pharmaceutical company, announced today the launch of TAVALISSE® (fostamatinib disodium hexahydrate) in Mexico, for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.1</p> <p align="justify">“Managing chronic ITP remains challenging, as patients often respond sub-optimally to available therapies and many continue to face a persistent risk of bleeding despite multiple treatment attempts. The introduction of fostamatinib in Mexico provides physicians with an important new therapeutic option, supported by solid clinical http://www.streetinsider.com/Press+Releases/Knight+Therapeutics+Announces+Launch+of+TAVALISSE%C2%AE+in+Mexico/26559343.html Wed, 27 May 2026 18:00:00 -0400 A.38925042 A.50201081 GUD O.01519837 O.03285412 O.17511696 http://www.streetinsider.com/Press+Releases/Knight+Therapeutics+Announces+Launch+of+TAVALISSE%C2%AE+in+Mexico/26559343.html <p align="justify">MONTREAL, May 27, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) (&quot;Knight&quot;) a pan-American (ex-US) pharmaceutical company, announced today the launch of TAVALISSE® (fostamatinib disodium hexahydrate) in Mexico, for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.1</p> <p align="justify">“Managing chronic ITP remains challenging, as patients often respond sub-optimally to available therapies and many continue to face a persistent risk of bleeding despite multiple treatment attempts. The introduction of fostamatinib in Mexico provides physicians with an important new therapeutic option, supported by solid clinical http://www.streetinsider.com/Press+Releases/Knight+Therapeutics+Announces+Launch+of+TAVALISSE%C2%AE+in+Mexico/26559343.html Wed, 27 May 2026 18:00:00 -0400 A.38925042 A.50201081 GUD O.01519837 O.03285412 O.17511696 http://www.streetinsider.com/Globe+Newswire/Knight+Therapeutics+Announces+Launch+of+TAVALISSE%C2%AE+in+Mexico/26559343.html <p align="justify">MONTREAL, May 27, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) (&quot;Knight&quot;) a pan-American (ex-US) pharmaceutical company, announced today the launch of TAVALISSE® (fostamatinib disodium hexahydrate) in Mexico, for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.1</p> <p align="justify">“Managing chronic ITP remains challenging, as patients often respond sub-optimally to available therapies and many continue to face a persistent risk of bleeding despite multiple treatment attempts. The introduction of fostamatinib in Mexico provides physicians with an important new therapeutic option, supported by solid clinical http://www.streetinsider.com/Globe+Newswire/Knight+Therapeutics+Announces+Launch+of+TAVALISSE%C2%AE+in+Mexico/26559343.html Wed, 27 May 2026 18:00:00 -0400 A.38925042 A.50201081 GUD O.01519837 O.03285412 O.17511696 http://www.streetinsider.com/Globe+Newswire/Knight+Therapeutics+Announces+Launch+of+TAVALISSE%C2%AE+in+Mexico/26559343.html <p align="justify">MONTREAL, May 27, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) (&quot;Knight&quot;) a pan-American (ex-US) pharmaceutical company, announced today the launch of TAVALISSE® (fostamatinib disodium hexahydrate) in Mexico, for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.1</p> <p align="justify">“Managing chronic ITP remains challenging, as patients often respond sub-optimally to available therapies and many continue to face a persistent risk of bleeding despite multiple treatment attempts. The introduction of fostamatinib in Mexico provides physicians with an important new therapeutic option, supported by solid clinical http://www.streetinsider.com/Globe+Newswire/Knight+Therapeutics+Announces+Launch+of+TAVALISSE%C2%AE+in+Mexico/26559343.html Wed, 27 May 2026 18:00:00 -0400 A.38925042 A.50201081 GUD O.01519837 O.03285412 O.17511696 http://www.streetinsider.com/Globe+Newswire/Knight+Therapeutics+Announces+Launch+of+TAVALISSE%C2%AE+in+Mexico/26559343.html <p align="justify">MONTREAL, May 27, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) (&quot;Knight&quot;) a pan-American (ex-US) pharmaceutical company, announced today the launch of TAVALISSE® (fostamatinib disodium hexahydrate) in Mexico, for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.1</p> <p align="justify">“Managing chronic ITP remains challenging, as patients often respond sub-optimally to available therapies and many continue to face a persistent risk of bleeding despite multiple treatment attempts. The introduction of fostamatinib in Mexico provides physicians with an important new therapeutic option, supported by solid clinical http://www.streetinsider.com/Globe+Newswire/Knight+Therapeutics+Announces+Launch+of+TAVALISSE%C2%AE+in+Mexico/26559343.html Wed, 27 May 2026 18:00:00 -0400 A.38925042 A.50201081 GUD O.01519837 O.03285412 O.17511696